Krystal Biotech Inc (KRYS)
177.41
-6.81
(-3.70%)
USD |
NASDAQ |
Nov 14, 16:00
177.41
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech Cash from Financing (Quarterly): 3.365M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.365M |
| June 30, 2024 | 10.64M |
| March 31, 2024 | 10.58M |
| December 31, 2023 | 2.619M |
| September 30, 2023 | 13.39M |
| June 30, 2023 | 185.27M |
| March 31, 2023 | 1.474M |
| December 31, 2022 | 3.069M |
| September 30, 2022 | 2.12M |
| June 30, 2022 | 30.70M |
| March 31, 2022 | -0.542M |
| December 31, 2021 | 202.07M |
| September 30, 2021 | 1.508M |
| June 30, 2021 | -0.199M |
| March 31, 2021 | 144.30M |
| December 31, 2020 | 0.141M |
| Date | Value |
|---|---|
| September 30, 2020 | 0.166M |
| June 30, 2020 | 117.47M |
| March 31, 2020 | 0.243M |
| December 31, 2019 | 0.299M |
| September 30, 2019 | 13.17M |
| June 30, 2019 | 94.02M |
| March 31, 2019 | 0.04M |
| December 31, 2018 | 64.29M |
| September 30, 2018 | 9.549M |
| June 30, 2018 | 0.004M |
| March 31, 2018 | 0.006M |
| December 31, 2017 | -0.693M |
| September 30, 2017 | 50.16M |
| June 30, 2017 | 1.999M |
| March 31, 2017 | 0.30M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.542M
Minimum
Mar 2022
202.07M
Maximum
Dec 2021
36.43M
Average
2.844M
Median
Cash from Financing (Quarterly) Benchmarks
| Bioventus Inc | 0.362M |
| ADMA Biologics Inc | -25.47M |
| Alnylam Pharmaceuticals Inc | 102.76M |
| Amicus Therapeutics Inc | 18.19M |
| Apellis Pharmaceuticals Inc | 2.542M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 58.86M |
| Cash from Investing (Quarterly) | -34.33M |
| Free Cash Flow | 58.06M |
| Free Cash Flow Per Share (Quarterly) | 1.933 |
| Free Cash Flow to Equity (Quarterly) | 57.81M |
| Free Cash Flow to Firm (Quarterly) | 57.81M |
| Free Cash Flow Yield | 1.11% |